Guess which ASX 200 share is up 7% after smashing FY24 guidance

This growing company has outperformed expectations in FY 2024 with another impressive 12 months.

| More on:
Ecstatic woman looking at her phone outside with her fist pumped.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is roaring higher on Tuesday morning.

At the time of writing, the ASX 200 share is up 7% to $25.79.

Why is this ASX 200 share jumping?

Investors have been buying the company's shares this morning after it released an update on its performance in FY 2024.

According to the release, fourth quarter unaudited revenue came in at approximately US$142 million (AU$218 million). This represents an increase of 46% over the prior year corresponding quarter and a 5% lift quarter-over-quarter.

Telix's revenue is currently generated predominantly from sales of Illuccix, its diagnostic radiopharmaceutical for prostate cancer PET2 imaging.

In light of this strong finish to the year, the ASX 200 share has outperformed its guidance for FY 2024.

It revealed that total unaudited full year revenue is up 55% year on year to approximately US$517 million (AU$783 million). This compares to its guidance range of US$490 million to US$510 million for the year.

Another positive is that the therapeutic and diagnostic radiopharmaceuticals company's investment into research and development (R&D) remains in line with guidance and is being funded by earnings generated from product sales.

Management commentary

The ASX 200 share's managing director and group chief executive officer, Dr. Christian Behrenbruch, was pleased with the company's performance in the fourth quarter. He said:

This has been another great quarter of commercial performance. Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. Boosting our balance sheet and the Nasdaq listing were major corporate milestones. The acquisition of FAP-targeting assets is a major addition to our superb product pipeline.

We are well-positioned for significant expansion, including planned launches of multiple imaging products in key markets and advancing late-stage therapeutic assets into pivotal trials. 2025 is shaping up to be transformative year for Telix.

Those late-stage therapeutic assets include its glioblastoma therapy candidate, TLX101. Based on positive feedback from its meeting with the US FDA, Telix is planning to move forward with an investigational new drug (IND) submission in the first half of 2025.

In addition, it will be progressing its kidney cancer therapy candidate, TLX250, and its prostate cancer therapy candidate, TLX591.

Telix also advised that intends to provide its FY 2025 guidance when it reports its audited FY 2024 results on 20 February 2025.

Following today's gain, the Telix share price is now up 140% over the past 12 months.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why is this ASX 200 healthcare share leaping 14% today?

Clarity Pharmaceuticals is the biggest gainer of the ASX 200 on Tuesday.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

Guess which ASX All Ords stock just leapt 9% on big US news

Investors are piling into this ASX All Ords stock on Tuesday. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Up 290% in 12 months: Why this ASX healthcare stock is surging again today

This stock is continuing its ascent on Tuesday. But why?

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Healthcare Shares

CSL is approaching a 5-year low. Is this a buying opportunity?

Let's see if analysts think investors should be buying the dip with this quality stock.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Pro Medicus shares are down 20%. Is this a buying opportunity?

One of the ASX’s best companies is now materially cheaper.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Orthocell shares up 10% today; anticipates FDA approval in the coming weeks

Some big news could be just days away for this growing regenerative medicine company.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

A quality ASX 200 share with 'limited to no impact' from Donald Trump's tariffs

A leading expert believes this ASX 200 company is now at an “attractive entry point”.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »